New York, November 07, 2024 - PRISM MarketView - Tilray Medical (NASDAQ: TLRY) has announced positive findings from a study examining the use of an oral cannabis extract for treating chemotherapy-induced nausea and vomiting (CINV). This condition, affecting up to 80% of cancer patients, is one of the most distressing side effects of chemotherapy, impacting patients’ quality of life, nutritional health, and overall well-being. The randomized, placebo-controlled trial involved 147 participants who received capsules containing THC and CBD or a placebo over six days. Results demonstrated a significant improvement in complete response rates, with 24% of those treated with the cannabis extract experiencing no vomiting or need for additional medications, compared to 8% in the placebo group. The treatment also reduced nausea and daily vomiting episodes, though some side effects, such as sedation and dizziness, were observed.
“These findings are encouraging for cancer patients undergoing chemotherapy. This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.”
Denise Faltischek, Chief Strategy Officer, and Head of International at Tilray Brands
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities